Standard of Care Treatment & Evolving Guidelines
At a Glance
The latest asthma guidelines no longer recommend using a rescue inhaler like albuterol alone. The new standard of care, called MART, uses a single combination inhaler to instantly open your airways while simultaneously treating the underlying inflammation that causes asthma attacks.
Asthma treatment has undergone its most significant transformation in over 50 years. For decades, the “blue inhaler” (albuterol) was the centerpiece of care. However, modern research has proven that using albuterol alone is not only outdated—it can be dangerous [1].
The Danger of “Albuterol-Only” Therapy
SABA (short-acting beta-agonist) inhalers like albuterol are excellent at relaxing the muscles around your airways. However, they do nothing to treat the underlying inflammation (the “fire”) [2].
Using albuterol alone masks your symptoms while the inflammation continues to worsen. This creates a “false sense of security” that significantly increases your risk of a life-threatening asthma attack [3]. Current Global Initiative for Asthma (GINA) 2024 guidelines now recommend that adults and adolescents should never be treated with SABA alone [1].
The Modern Standard: Track 1 (MART)
The preferred treatment approach is now called Maintenance and Reliever Therapy (MART), or “Track 1” [1].
In this approach, you use a single combination inhaler—typically containing low-dose ICS (an inhaled corticosteroid to treat inflammation) and formoterol (a long-acting but fast-starting medicine to open the airways) [4]. Depending on the severity of your asthma, this can be prescribed in two ways:
- As-needed only (for mild asthma): You only take puffs when you feel symptoms.
- Maintenance and Reliever (for moderate to severe asthma): You take a daily maintenance dose (e.g., 1-2 puffs morning and night), PLUS you use the exact same inhaler whenever you feel breakthrough symptoms [5].
The crucial benefit is that every time you reach for your “reliever” because you feel tight, you are automatically giving yourself an extra dose of anti-inflammatory medicine to “put out the fire” [1].
Addressing “Steroid Phobia”
It is normal to feel worried about taking a daily “steroid.” However, inhaled corticosteroids (ICS) are highly targeted. They deliver micro-doses directly to your lungs, which is vastly different from the high-dose systemic oral steroid pills (like prednisone) that cause weight gain, immune suppression, and other severe side effects. ICS is safe and essential for long-term daily use.
Biologics: Precision Medicine for Severe Asthma
If your asthma remains uncontrolled despite using a high-dose combination inhaler, you may have severe asthma. For these cases, doctors use biologics—specialized, injectable medications that target specific immune pathways [6].
The choice of biologic is based on your specific “biomarkers”. These acronyms (like IL5 or TSLP) simply refer to specific “messenger proteins” or chemical switches in your immune system that are causing the inflammation:
| Biologic Type | Target “Switch” | Best For… | Side Effects Note |
|---|---|---|---|
| Anti-IgE | Allergy antibodies | Patients with clear allergic triggers and high IgE [7] | Injection site reactions are common. |
| Anti-IL5 / IL5R | Eosinophils | Patients with high blood eosinophil counts (“Eosinophilic Asthma”) [8] | Generally well-tolerated; requires scheduled dosing. |
| Anti-IL4R | Dual immune pathway | Patients with high eosinophils and history of eczema/nasal polyps [6] | May cause initial, temporary rise in eosinophils. |
| Anti-TSLP | The “Alarm” signal | The newest class; works “upstream” to block the initial trigger response [9] | Broad application across different phenotypes. |
Treatment Decision Framework
Your care should generally follow this hierarchy based on your symptom frequency:
- Infrequent Symptoms: As-needed low-dose ICS-formoterol (No daily dose needed).
- Regular Symptoms: Daily low-dose ICS-formoterol plus as-needed puffs of the same inhaler (Track 1/MART).
- Uncontrolled on Track 1: Increase maintenance dose and investigate “T2-high” biomarkers.
- Severe/Refractory: Consider adding a LAMA (a third type of medicine) or starting a biologic therapy [1][8].
If your current treatment plan relies only on a “rescue” inhaler without a daily anti-inflammatory component, it is important to discuss the updated GINA 2024 guidelines with your doctor.
Common questions in this guide
Why shouldn't I use an albuterol-only rescue inhaler?
What is the MART approach for asthma treatment?
Are inhaled daily steroids safe for asthma?
How do I know if I need a biologic for my asthma?
How many rescue inhalers is it normal to use in a year?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Am I on 'Track 1' (MART) with an ICS-formoterol inhaler, or am I still using an older albuterol-only approach?
- 2.If I am only using a blue rescue inhaler, can we discuss why the GINA 2024 guidelines now recommend adding an anti-inflammatory medicine to every dose?
- 3.My asthma is still not controlled; can we re-check my blood eosinophils and FeNO to see if I qualify for a biologic?
- 4.If we start a biologic like anti-IL5 or anti-TSLP, how long should it take before I notice an improvement in my breathing?
- 5.Can we review my inhaler technique to make sure the maintenance medicine is actually reaching my lower airways?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (9)
- 1
Update on Asthma Management Guidelines.
Dubin S, Patak P, Jung D
Missouri medicine 2024; (121(5)):364-367.
PMID: 39421468 - 2
GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents.
Reddel HK, FitzGerald JM, Bateman ED, et al.
The European respiratory journal 2019; (53(6)) doi:10.1183/13993003.01046-2019.
PMID: 31249014 - 3
Asthma management in low and middle income countries: case for change.
Mortimer K, Reddel HK, Pitrez PM, Bateman ED
The European respiratory journal 2022; (60(3)) doi:10.1183/13993003.03179-2021.
PMID: 35210321 - 4
Maintenance and Reliever Therapy in Pediatric Asthma: A Concise Review of Recent Evidence-Part I.
Alharbi R, Alharbi AS
Pediatric annals 2025; (54(10)):e367-e371 doi:10.3928/19382359-20250828-07.
PMID: 41060060 - 5
Does asthma treatment influence COVID-19 severity? A comparative cohort study of SMART vs. Traditional therapy.
Li Y, Chen W, Hill R, et al.
European clinical respiratory journal 2026; (13(1)):2683007 doi:10.1080/20018525.2026.2683007.
PMID: 42266192 - 6
Retrospective Analysis of Biologic Agent Utilization in Severe Asthma: Impact on Exacerbation Rates, Forced Expiratory Volume in the First Second (FEV1), Eosinophils, and IgE Levels.
Khan AR, Waqar S, Rafiq Z, et al.
Cureus 2023; (15(8)):e42818 doi:10.7759/cureus.42818.
PMID: 37674970 - 7
Relapsing Eosinophilia in a Severe Allergic Asthma Patient on Biological Therapy.
Raduna O, Oprescu B, Mihaicuta S, Frent S
Journal of clinical medicine 2024; (13(12)) doi:10.3390/jcm13123402.
PMID: 38929930 - 8
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
Panettieri R, Lugogo N, Corren J, Ambrose CS
Journal of asthma and allergy 2024; (17()):219-236 doi:10.2147/JAA.S342391.
PMID: 38524099 - 9
Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review.
Korn S, Cook B, Simpson LJ, et al.
Advances in therapy 2023; (40(7)):2944-2964 doi:10.1007/s12325-023-02514-0.
PMID: 37233876
This page provides educational information about current asthma treatment guidelines and medications. It does not replace professional medical advice; always consult your pulmonologist or healthcare provider before altering your asthma management plan.
Get notified when new evidence is published on asthma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.